Checkpoint Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Checkpoint Therapeutics's estimated annual revenue is currently $5M per year.
- Checkpoint Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Checkpoint Therapeutics has 25 Employees.
- Checkpoint Therapeutics grew their employee count by 4% last year.
Checkpoint Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Head Biologics Technical Operations | Reveal Email/Phone |
4 | SVP, Product Development and Regulatory Affairs | Reveal Email/Phone |
5 | Sr VP Checkpoint Therapeutics | Reveal Email/Phone |
6 | Sr. Director Operations and Supply Chain | Reveal Email/Phone |
7 | Director Quality Assurance | Reveal Email/Phone |
8 | Senior Director, Regulatory Affairs CMC | Reveal Email/Phone |
9 | Quality Systems Director | Reveal Email/Phone |
10 | Director, Program Management | Reveal Email/Phone |
Checkpoint Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 61 | 7% | N/A | N/A |
#2 | $354.3M | 461 | -2% | $567.1M | N/A |
#3 | $377.1M | 1876 | -1% | N/A | N/A |
#4 | $7.8M | 39 | 8% | N/A | N/A |
#5 | $5.4M | 27 | 0% | N/A | N/A |
#6 | $45M | 224 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -82% | N/A | N/A |
#8 | $9.2M | 46 | 12% | N/A | N/A |
#9 | N/A | 694 | 46% | N/A | N/A |
#10 | $15.5M | 77 | 5% | N/A | N/A |
What Is Checkpoint Therapeutics?
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
keywords:N/A
N/A
Total Funding
25
Number of Employees
$5M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 25 | -4% | N/A |
#2 | $2.8M | 25 | 4% | N/A |
#3 | $1.8M | 25 | 4% | $48.9M |
#4 | $1.8M | 25 | -22% | $1.6M |
#5 | $1.8M | 25 | -29% | $67M |